{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:27Z","timestamp":1787020827634,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030313987"],"award-info":[{"award-number":["2018A030313987"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Traditional Medicine Bureau of Guangdong Province","award":["20164015"],"award-info":[{"award-number":["20164015"]}]},{"name":"Chinese Traditional Medicine Bureau of Guangdong Province","award":["20183009"],"award-info":[{"award-number":["20183009"]}]},{"name":"Chinese Traditional Medicine Bureau of Guangdong Province","award":["20202119"],"award-info":[{"award-number":["20202119"]}]},{"name":"soft science research program of Guangdong Province","award":["2018B020207009"],"award-info":[{"award-number":["2018B020207009"]}]},{"name":"Integrated Hospital of Traditional Chinese Medicine, Southern Medical University","award":["1201902003"],"award-info":[{"award-number":["1201902003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shende\u2019an tablet (SDA) is a newly capsuled Chinese herbal formula derived from the Chinese traditional medicine Zhengan Xifeng Decoction which is approved for the treatment of neurasthenia and insomnia in China. This study aimed to investigate the neuroprotective effects of SDA against Parkinson\u2019s disease (PD) in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the present work, the neuroprotective effects and mechanism of SDA were evaluated in the cellular PD model. Male C57BL\/6J mice were subject to a partial MPTP lesion alongside treatment with SDA. Behavioural test and tyrosine-hydroxylase immunohistochemistry were used to evaluate nigrostriatal tract integrity. HPLC analysis and Western blotting were used to assess the effect of SDA on dopamine metabolism and the expression of HO-1, PGC-1\u03b1 and Nrf2, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results demonstrated that SDA had neuroprotective effect in dopaminergic PC12 cells with 6-OHDA lesion. It had also displayed efficient dopaminergic neuronal protection and motor behavior alleviation properties in MPTP-induced PD mice. In the PC12 cells and MPTP-induced Parkinson\u2019s disease animal models, SDA was highly efficacious in \u03b1-synuclein clearance associated with the activation of PGC-1\u03b1\/Nrf2 signal pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SDA demonstrated potential as a future therapeutic modality in PD through protecting dopamine neurons and alleviating the motor symptoms, mediated by the activation of PGC-1\u03b1\/Nrf2 signal pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-021-00429-y","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T16:03:44Z","timestamp":1612800224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neuroprotective effects of Shende\u2019an tablet in the Parkinson\u2019s disease model"],"prefix":"10.1186","volume":"16","author":[{"given":"Xiaoyan","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7512-8138","authenticated-orcid":false,"given":"Sai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72:1\u2013136.","journal-title":"Neurology"},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41401-020-0365-y","volume":"41","author":"Q Mao","year":"2020","unstructured":"Mao Q, Qin WZ, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson\u2019s disease. Acta Pharmacol Sin. 2020;41:471\u201382.","journal-title":"Acta Pharmacol Sin"},{"key":"429_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018;17:804\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41401-020-0369-7","volume":"41","author":"XC Zhen","year":"2020","unstructured":"Zhen XC, Chu HY. Emerging novel approaches to drug research and diagnosis of Parkinson\u2019s disease. Acta Pharmacol Sin. 2020;41:439\u201341.","journal-title":"Acta Pharmacol Sin"},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11:6\u201323.","journal-title":"Neurotherapeutics"},{"issue":"Suppl 3","key":"429_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P. Oxidative stress in Parkinson\u2019s disease. Ann Neurol. 2003;53(Suppl 3):26\u201338, S36-S38.","journal-title":"Ann Neurol"},{"issue":"5646","key":"429_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1087753","volume":"302","author":"TM Dawson","year":"2003","unstructured":"Dawson TM. Molecular pathways of neurodegeneration in Parkinson\u2019s disease. Science. 2003;302(5646):819\u201322.","journal-title":"Science"},{"key":"429_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"429_CR9","first-page":"61","volume":"00","author":"YX Zheng","year":"1986","unstructured":"Zheng YX, Yang HY. Pharmacology research of Shende\u2019an. Pharmacol&nbsp; Clin Chinese Materia Medica. 1986;00:61\u20133.","journal-title":"Pharmacol&nbsp; Clin Chinese Materia Medica."},{"key":"429_CR10","first-page":"47","volume":"00","author":"KQ Wu","year":"1986","unstructured":"Wu KQ, Hong J. Clinical observation of Shende\u2019an in the treatment of 80 cases of neurasthenia. Pharmacol Clin Chinese Materia Medica. 1986;00:47\u20138.","journal-title":"Pharmacol Clin Chinese Materia Medica."},{"key":"429_CR11","unstructured":"Li S, Peng K, Zhang X, Wen XM, Sheng XY, Luo XJ, Wang CY, Ma GL. The invention relates to a Chinese traditional medicine composition for the treatment of Parkinson\u2019s disease and its preparation and application. CN 109568439 A. 2019-01-04."},{"issue":"1","key":"429_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc. 2007;2(1):141\u201351.","journal-title":"Nat Protoc"},{"issue":"1\u20132","key":"429_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0006-8993(90)90576-W","volume":"515","author":"N Arai","year":"1990","unstructured":"Arai N, Misugi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetra- hydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 1990;515(1\u20132):57\u201363.","journal-title":"Brain Res"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuroscience.2011.11.036","volume":"202","author":"XQ Bao","year":"2012","unstructured":"Bao XQ, Kong XC, Qian C, Zhang D. FLZ protects dopaminergic neuron through activating protein kinase B\/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson\u2019s disease models. Neuroscience. 2012;202:396\u2013404.","journal-title":"Neuroscience"},{"key":"429_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pbb.2014.03.028","volume":"122","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Lai D, Wang L, Yu P, Zhu L, Guo B, et al. Neuroprotective effects of the andrographolide analogue AL-1\u00a0in the MPP(+)\/MPTP-induced Parkinson\u2019s disease model in vitro and in mice. Pharmacol Biochem Behav. 2014;122:191\u2013202.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"429_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cdd.2008.110","volume":"16","author":"S Sarkar","year":"2009","unstructured":"Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009;16(1):46\u201356.","journal-title":"Cell Death Differ"},{"issue":"6","key":"429_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nchembio883","volume":"3","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, et al. Small molecules enhance autophagy and reduce toxicity in Huntington\u2019s disease models. Nat Chem Biol. 2007;3(6):331\u20138.","journal-title":"Nat Chem Biol"},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose A, Beal MF. Mitochondrial dysfunction in Parkinson\u2019s disease. J Neurochem. 2016;139:216\u201331.","journal-title":"J Neurochem"},{"issue":"4","key":"429_CR19","first-page":"1817","volume":"41","author":"JD Guo","year":"2018","unstructured":"Guo JD, Zhao X, Li Y, Li GR, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson\u2019s disease (review). Int J Mol Med. 2018;41(4):1817\u201325.","journal-title":"Int J Mol Med"},{"key":"429_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fnmol.2018.00236","volume":"11","author":"Z Wei","year":"2018","unstructured":"Wei Z, Li X, Li X, Liu Q, Cheng Y. Oxidative stress in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Mol Neurosci. 2018;11:236.","journal-title":"Front Mol Neurosci"},{"key":"429_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/DDDT.S130514","volume":"11","author":"G Ganguly","year":"2017","unstructured":"Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer\u2019s disease and Parkinson\u2019s disease. Drug Des Devel Ther. 2017;11:797\u2013810.","journal-title":"Drug Des Devel Ther"},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106\u2013107","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol. 2013;106\u2013107:17\u201332.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"429_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","volume":"318","author":"A Schober","year":"2004","unstructured":"Schober A. Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215\u201324.","journal-title":"Cell Tissue Res"},{"issue":"3","key":"429_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0304-3940(00)00948-4","volume":"283","author":"D Blum","year":"2000","unstructured":"Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett. 2000;283(3):193\u20136.","journal-title":"Neurosci Lett"},{"issue":"4","key":"429_CR25","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","volume":"74","author":"R Soto-Otero","year":"2000","unstructured":"Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson\u2019s disease. J Neurochem. 2000;74(4):1605\u201312.","journal-title":"J Neurochem"},{"issue":"2","key":"429_CR26","doi-asserted-by":"publisher","first-page":"a9399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2011","unstructured":"Stefanis L. alpha-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2011;2(2):a9399.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"429_CR27","first-page":"1","volume":"2014","author":"A Xie","year":"2014","unstructured":"Xie A, Gao J, Xu L, Meng D. Shared mechanisms of neurodegeneration in Alzheimer\u2019s disease and Parkinson\u2019s disease. BioMed Res Int. 2014;2014:1\u20138.","journal-title":"BioMed Res Int"},{"issue":"1","key":"429_CR28","doi-asserted-by":"publisher","first-page":"a8888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A. Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2(1):a8888.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"429_CR29","first-page":"717","volume":"10","author":"M Hashimoto","year":"1999","unstructured":"Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, et al. Oxidative stress induces amyloid-like aggregate formation of NACP\/alpha-synuclein in vitro. Neuro Report. 1999;10(4):717\u201321.","journal-title":"Neuro Report"},{"issue":"6","key":"429_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0891-5849(02)00741-4","volume":"32","author":"KS Kim","year":"2002","unstructured":"Kim KS, Choi SY, Kwon HY, Won MH, Kang TC, Kang JH. Aggregation of alpha-synuclein induced by the Cu, Zn superoxide dismutase and hydrogen peroxide system. Free Radical Biol Med. 2002;32(6):544\u201350.","journal-title":"Free Radical Biol Med"},{"key":"429_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-015-0067-y","volume":"11","author":"M Baranyi","year":"2016","unstructured":"Baranyi M, Porceddu PF, Goloncser F, Kulcsar S, Otrokocsi L, Kittel A, et al. Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson\u2019s disease. Mol Neurodegener. 2016;11:6.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"429_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1523\/ENEURO.0183-16.2016","volume":"3","author":"H Jiang","year":"2016","unstructured":"Jiang H, Kang SU, Zhang S, Karuppagounder S, Xu J, Lee YK, et al. Adult conditional knockout of PGC-1alpha leads to loss of dopamine neurons. eNeuro. 2016;3(4):1\u20138.","journal-title":"eNeuro"},{"issue":"7","key":"429_CR33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00018-011-0850-z","volume":"69","author":"G Mudo","year":"2012","unstructured":"Mudo G, Makela J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, et al. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease. Cell Mol Life Sci. 2012;69(7):1153\u201365.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"429_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neulet.2010.02.034","volume":"473","author":"AS Ebrahim","year":"2010","unstructured":"Ebrahim AS, Ko LW, Yen SH. Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1\u03b1 enhances \u03b1-synuclein oligomerization and down regulates AKT\/GSK3\u03b2 signaling pathway in human neuronal cells that inducibly express \u03b1-synuclein. Neurosci Lett. 2010;473(2):120\u20135.","journal-title":"Neurosci Lett"},{"issue":"52","key":"429_CR35","doi-asserted-by":"publisher","first-page":"52r","DOI":"10.1126\/scitranslmed.3001059","volume":"2","author":"B Zheng","year":"2010","unstructured":"Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson\u2019s disease. Sci Transl Med. 2010;2(52):52r\u201373r.","journal-title":"Sci Transl Med"},{"issue":"5","key":"429_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1242\/dmm.007575","volume":"4","author":"MC Barone","year":"2011","unstructured":"Barone MC, Sykiotis GP, Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson\u2019s disease. Dis Model Mech. 2011;4(5):701\u20137.","journal-title":"Dis Model Mech"},{"issue":"14","key":"429_CR37","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1093\/hmg\/dds143","volume":"21","author":"I Lastres-Becker","year":"2012","unstructured":"Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, R\u00e1bano A, Kirik D, et al. \u03b1-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson\u2019s disease. Hum Mol Genet. 2012;21(14):3173\u201392.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"429_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/ars.2008.2241","volume":"11","author":"J Clark","year":"2009","unstructured":"Clark J, Simon DK. Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson\u2019s disease. Antioxid Redox Signal. 2009;11(3):509\u201328.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"429_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.14336\/AD.2017.0831","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Hao J, Zheng Y, Su R, Liao Y, Gong X, et al. Fucoidan protects dopaminergic neurons by enhancing the mitochondrial function in a Rotenone-induced rat model of Parkinson\u2019s disease. Aging Dis. 2018;9(4):590\u2013604.","journal-title":"Aging Dis"},{"key":"429_CR40","doi-asserted-by":"publisher","first-page":"9179","DOI":"10.1021\/acs.jmedchem.5b01031","volume":"58","author":"B Das","year":"2015","unstructured":"Das B, Vedachalam S, Luo D, Antonio T, Reith MEA, Dutta AK. Development of a highly potent D2\/D3 agonist and a partial agonist from structure-activity relationship study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: implication in the treatment of Parkinson\u2019s disease. J Med Chem. 2015;58:9179\u201395.","journal-title":"J Med Chem"},{"issue":"3","key":"429_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51(3):347\u201372.","journal-title":"J Med Chem"},{"key":"429_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.fitote.2012.12.009","volume":"84","author":"XZ Li","year":"2013","unstructured":"Li XZ, Zhang SN, Liu SM, Lu F. Recent advances in herbal medicines treating Parkinson\u2019s disease. Fitoterapia. 2013;84:273\u201385.","journal-title":"Fitoterapia"},{"issue":"34","key":"429_CR43","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.2174\/0929867326666190527120614","volume":"27","author":"Z Wang","year":"2020","unstructured":"Wang Z, He C, Shi JS. Natural products for the treatment of neurodegenerative diseases. Curr Med Chem. 2020;27(34):5790\u2013828.","journal-title":"Curr Med Chem"}],"updated-by":[{"DOI":"10.1186\/s13020-024-00965-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000}}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-021-00429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-021-00429-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-021-00429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T04:15:51Z","timestamp":1723522551000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-021-00429-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1186\/s13020-021-00429-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-29059\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29059\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29059\/v3","asserted-by":"object"}]},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,6]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13020-024-00965-3","URL":"https:\/\/doi.org\/10.1186\/s13020-024-00965-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures in this study were approved and supervised by the animal research ethical committee of Southern Medical University, and strictly obeyed the rules of animal experiment ethic to reduced number as well as suffering of animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}